Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384215 · ClinicalTrials.gov registry record · Phase 4
Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 352
- Enrollment target
NCT00384215 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 352 participants.
The verdict
NCT00384215, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 352 participants
- Enrollment target
Study Summary
This trial will explore the various advantages and possible disadvantages of pioglitazone and insulin glargine when added to monotherapy. Glycemic control, hypoglycemia, weight, lipid profiles, quality of life and cost will be studied given a comprehensive set of data that may help future treatment decisions.
Interventions
- DRUG insulin glargine [rDNA origin] injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2001-12 |
| Est. Completion | 2005-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384215
The ClinicalTrials.gov registry entry for NCT00384215 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which insulin glargine [rDNA origin] injection is the first listed.
NCT00384215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00384215 about?
NCT00384215 is a clinical study titled "Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin". This trial will explore the various advantages and possible disadvantages of pioglitazone and insulin glargine when added to monotherapy. Glycemic control, hypoglycemia, weight, lipid profiles, quality of life and cost will be studied given a comprehensive set of data that may help future treatment ...
What is the current status of trial NCT00384215?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 352 participants. The study started on 2001-12. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00384215?
The interventions under investigation include: insulin glargine [rDNA origin] injection (DRUG).
Who is sponsoring clinical trial NCT00384215?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.